Weekly administration of recombinant human erythropoietin (rHuEPO) reduces the need for blood transfusions in critically ill patients but may not improve survival, according to a report in the Dec. 11 issue of The Journal of The American Medical Association. An accompanying editorial highlights the need for cost-effectiveness studies.
“While it is clear that rHuEPO treatment reduces red blood cell (RBC) transfusions in critically ill patients, further study is necessary to establish whether this reduction in RBC transfusions will also result in improved clinical outcomes for some critically ill patients,” write Howard L. Corwin, MD, of Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, and colleagues.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!